Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Mar 31;11(6):270.
doi: 10.21037/atm-23-165. Epub 2023 Feb 14.

Sequence of therapies for advanced BRAFV600E/K melanoma

Maria Gonzalez-Cao  1 , Rafael Rosell  1   2 , Salvador Martin Algarra  3 , Teresa Puertolas  4 , Enrique Espinosa  5
Affiliations
Editorial

Sequence of therapies for advanced BRAFV600E/K melanoma

Maria Gonzalez-Cao et al. Ann Transl Med. .
No abstract available

Keywords: BRAF; CTLA-4; immunotherapy; melanoma; programmed death 1 (PD-1).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-23-165/coif). MGC, SMA, TP, and EE received honoraria for lectures and tavel grant from MSD, BMS, Novartis and Pierre Fabre. SMA, TP and EE received honoraria for consulting fees from MSD, BMS, Novartis and Pierre Fabre. RR serves as the Honorary Editor-in-Chief of Annals of Translational Medicine from June 2019 to May 2024.

Comment on

References

    1. Robert C, Grob JJ, Stroyakovskiy D, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med 2019;381:626-36. 10.1056/NEJMoa1904059 - DOI - PubMed
    1. Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016;17:1248-60. 10.1016/S1470-2045(16)30122-X - DOI - PubMed
    1. Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2018;19:603-15. 10.1016/S1470-2045(18)30142-6 - DOI - PubMed
    1. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2019;381:1535-46. 10.1056/NEJMoa1910836 - DOI - PubMed
    1. Hodi FS, -Sileni VC, Lewis KD, et al. Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067. J Clin Oncol 2022;40:abstr 9522.